US prostate cancer care is moving further away from immediate treatment for low-risk disease, according to an analysis published in CANCER. Across several major datasets, the researchers found both a decline in the share of patients diagnosed with low-risk prostate cancer and a sharp rise in the use of active surveillance instead of radiation or surgery.
The shift matters because many localized, low-risk prostate cancers grow slowly and may never threaten a patient’s life. Treating every such cancer can expose patients to the harms of therapy without delivering a meaningful benefit. The new analysis suggests that concerns about overdiagnosis and overtreatment are increasingly being reflected in clinical practice.
What the researchers examined
Investigators reviewed localized prostate cancer cases in three US data sources: the Surveillance, Epidemiology, and End Results Program, or SEER, from 2010 through 2023; the Veterans Affairs health system from 2010 through 2024; and the Michigan Radiation Oncology Quality Consortium from 2021 through 2025.
That combination offers a view across a large population-based cancer registry, an integrated federal health system, and a more recent quality-focused radiation cohort. The analysis was designed to assess whether recommendations favoring surveillance for low-risk prostate cancer have corresponded with less treatment in real-world care.
During the 2010s, guidance around prostate-specific antigen, or PSA, screening changed amid concern that screening could identify slow-growing cancers and lead to unnecessary treatment. Guidelines subsequently supported active surveillance for localized, low-risk disease, while clinicians and patients weighed cancer control against the possible side effects of intervention.
Low-risk diagnoses declined
The study found that low-risk cancer made up a smaller share of prostate cancer diagnoses over time. In SEER, the proportion declined from 28.8% to 24.0%. In the VA system, it declined from 32.3% to 21.9%.
The changes do not mean low-risk disease has disappeared, nor do they establish a single cause for the decline. But lead author Steven M. Monda of the University of Michigan said the moderate reduction in low-risk diagnoses likely reflects greater use of magnetic resonance imaging in screening. Better diagnostic pathways may help clinicians focus biopsies and identify cancers that warrant closer attention.
For patients, the key point is that a diagnosis is increasingly being paired with a more refined assessment of risk. Low-risk prostate cancer is not the same as an urgent need for surgery or radiation. Care can be tailored to the likely behavior of the disease and to the patient’s circumstances.
Surveillance became the prevailing approach
The much larger change was in management after diagnosis. Among patients with low-risk cancer, the proportion receiving neither radiation nor prostate removal rose from 33.6% to 83.4% in SEER by 2023. In the VA system, it rose from 51.6% to 96.3% by 2024.
In this context, receiving neither treatment does not imply that care has stopped. Active surveillance is a management strategy for monitoring low-risk prostate cancer over time rather than immediately attempting to remove or destroy it. The approach reflects the possibility that some tumors can be watched safely while preserving treatment options if the cancer’s risk profile changes.
The result is a substantial reversal from an era in which a low-risk diagnosis more commonly led directly to intervention. The study’s findings indicate that surveillance is now widely used across very different care settings, rather than remaining a niche alternative available only at selected centers.
Radiation use among low-risk cases also fell
The analysis also tracked the risk profile of patients treated with radiation for localized prostate cancer. Among 207,196 patients receiving radiation, the proportion with low-risk disease dropped from 33.7% to 6.5% in SEER and from 22.9% to 2.0% in the VA system.
In the newer Michigan consortium data, the share of radiation-treated patients with low-risk disease remained low, ranging from 2.8% to 4.2% between 2021 and 2025. Taken together, the figures point to a narrower use of radiation for patients whose cancer is least likely to require immediate treatment.
The study does not argue that radiation or prostate removal are never appropriate. Its findings instead describe a broad change in how clinicians are matching treatment intensity to disease risk. Men with low-risk cancer may still have individual medical, clinical, or personal reasons to choose treatment, while others may be suited to surveillance.
A change in the balance of prostate cancer care
Prostate cancer screening and treatment have long involved a difficult balance. Finding cancer early can create opportunities for care, but identifying a cancer is not by itself proof that aggressive treatment will improve outcomes. The risks of overtreatment have been a central part of debate over PSA-based screening.
This analysis suggests the system is adapting to that challenge. Fewer low-risk cancers are being diagnosed in the datasets studied, and patients who are diagnosed with such disease are much less likely to receive radiation or surgery right away.
For clinicians, the trend reinforces the importance of discussing risk category and management options clearly. For patients, it underscores that surveillance is an established care pathway for appropriately selected low-risk cancer, not an absence of care. Decisions still require individual medical guidance, but the national direction is clear: low-risk prostate cancer is increasingly being monitored rather than automatically treated.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
